Full Breakdown
Judge Reyes Links Pentagon Testosterone Initiative to Transgender Ban Lawsuit
7/23/2026, 6:22:20 AM
Core Event
U.S. District Judge Ana Reyes, a Biden appointee overseeing *Talbott v. Trump*, issued an order on July 22 requiring the Department of Defense to explain why a newly announced “High-T” testosterone screening and replacement program for service members is treated as a readiness benefit while the administration’s 2025 executive order bars transgender personnel who receive hormone therapy. The order asks the parties to compare the medical and logistical aspects of testosterone replacement therapy (TRT) for cisgender troops with the hormone care provided to transgender men and to detail the policy’s cost and screening procedures.
Background & Context
The ban has been challenged by transgender active-duty members and former service members since late January 2025. Judge Reyes blocked the ban in March 2025, a decision later partially upheld by a divided D.C. Circuit panel, which sent the case back for further review. In June 30, Reyes certified a class covering transgender service members and prospective recruits, expanding the potential impact of any final ruling.
Timeline
- July 15 – Defense Secretary Pete Hegseth announces mandatory annual testosterone deficiency screening for all service members 30 and older (voluntary testing for younger troops).
- July 22 – Judge Reyes orders the government to address six issues linking the “High-T” plan to the transgender ban.
- August 7 – Briefing deadline for parties.
- September 4 – Expert reports due; September 25 – Rebuttal reports due.
- October 16 – Discovery closes.
- November 13 – Summary-judgment motions due; responses due December 14.
- August 30 (scheduled) – Government attorneys plan to petition the Supreme Court.
- January 4 (scheduled) – Two-week trial begins.
Data & Statistics
- The Pentagon has cited $52 million in spending on gender-dysphoria-related care from 2015-2024, averaging $5.2 million per year.
- In 2023 the military spent roughly $41 million on Viagra, a figure Judge Reyes noted to illustrate the relative scale of transgender-care costs.
- Hegseth’s program targets all service members 30 and older, including women, with annual testosterone screening; younger personnel may request testing voluntarily.
Official Statements & Responses
Reyes directed both plaintiffs and the government to submit expert declarations on medical guidelines, monitoring protocols, logistical demands, and cost differentials between TRT for cisgender troops and hormone therapy for transgender men.
Shannon Minter, legal director of the National Center for LGBTQ+ Rights (NCLR) and lead counsel for the plaintiffs, said the request for detailed information is essential to determine whether the testosterone policy undermines the government’s justification for the transgender ban.
The Pentagon declined to comment publicly, citing the pending litigation.
Verbatim Quotes
- “The Court must assess the impact of this newly announced policy on the parties’ positions,” — Ana Reyes
- “We owe our warriors the absolute best medical care in the world, and this program delivers on that obligation,” — Pete Hegseth
What’s Next
The parties must file briefs on the six issues by August 7. Expert reports are due September 4, with rebuttals by September 25. Discovery closes October 16, followed by summary-judgment motions on November 13 and responses on December 14. Government attorneys intend to petition the Supreme Court by August 30, and a two-week trial is slated to begin January 4. The outcome could set precedent for how the military treats hormone-based medical care across all service members.
